Intercept Pharmaceuticals (ICPT) Getting Somewhat Favorable Press Coverage, Analysis Shows

News coverage about Intercept Pharmaceuticals (NASDAQ:ICPT) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intercept Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.3271479338734 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at $56.53 on Thursday. The firm has a market cap of $1,414.50, a price-to-earnings ratio of -3.82 and a beta of -2.05. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 3.15. Intercept Pharmaceuticals has a 12-month low of $54.98 and a 12-month high of $135.59.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.48) by $0.59. The business had revenue of $41.33 million during the quarter, compared to analysts’ expectations of $36.95 million. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The firm’s revenue for the quarter was up 697.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($3.59) EPS. equities research analysts expect that Intercept Pharmaceuticals will post -13.36 earnings per share for the current fiscal year.

ICPT has been the topic of a number of research analyst reports. Royal Bank of Canada initiated coverage on shares of Intercept Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $244.00 price target on the stock. Laidlaw decreased their price target on shares of Intercept Pharmaceuticals from $118.00 to $90.00 and set a “hold” rating on the stock in a report on Friday, September 22nd. Cantor Fitzgerald raised shares of Intercept Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $69.00 price target on the stock in a report on Wednesday, November 1st. Deutsche Bank initiated coverage on shares of Intercept Pharmaceuticals in a report on Tuesday, December 12th. They set a “buy” rating and a $106.00 target price on the stock. Finally, Wells Fargo & Co reaffirmed an “outperform” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, September 13th. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $141.58.

WARNING: “Intercept Pharmaceuticals (ICPT) Getting Somewhat Favorable Press Coverage, Analysis Shows” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

What are top analysts saying about Intercept Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intercept Pharmaceuticals and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit